Front Page News
Cure SMA Awards $150,000 Grant to Brunhilde Wirth, PhD, Institute of Cologne, Germany
Cure SMA has awarded a $150,000 research grant to Brunhilde Wirth, PhD, at Institute of Cologne, Germany, for her project, “Study of combinatorial therapy based […]
Read More ›Cure SMA Awards $50,000 Grant to Rashmi Kothary, PhD, University of Ottawa
Cure SMA has awarded a $50,000 research grant to Rashmi Kothary, PhD, at the University of Ottawa, for his project, ” The shifting landscape of […]
Read More ›Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015 for the Treatment of Patients with SMA
Scholar Rock today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead antibody product candidate, SRK-015, […]
Read More ›Cure SMA Awards $150,000 Grant to Robin Parks, PhD, University of Ottawa
Cure SMA has awarded a $150,000 research grant to Robin Parks, PhD, at the University of Ottawa, for his project, “Serum-derived exosomes as a biomarker […]
Read More ›Cure SMA Welcomes Back Biogen as a National Premier Partner for 2018
Cure SMA is thrilled to welcome Biogen back as a National Premier Partner for 2018. As a part of their partnership, Biogen will be sponsoring […]
Read More ›House and Senate Vote to Increase Federal Funding for Newborn Screening Programs
Today, Congress passed a new federal spending bill, increasing funding for several critical newborn screening programs, that the President also signed. The bill increases funding for the […]
Read More ›Cure SMA Awards $150,000 Grant to Charlotte Sumner, MD, Johns Hopkins University
Cure SMA has awarded a $150,000 research grant to Charlotte Sumner, MD, at Johns Hopkins University, for her project, “Testing the potential of SMN-AS1 as […]
Read More ›Record Number of Abstracts Submitted for 2018 SMA Researcher Meeting
Abstract submission is now closed for the 2018 SMA Researcher Meeting. We are excited to announce that we received 128 submissions, a record number. Our […]
Read More ›The Discovery of SMA
In 2016, the spinal muscular atrophy community celebrated the approval of the first-ever treatment that targets the underlying genetic cause of SMA. This was a […]
Read More ›Roche Releases Community Statement on RG7916 and Olesoxime Programs
Roche has provided the following community statement on RG7916 and Olesoxime investigational programs. Dear SMA Community, We are very pleased to share an update of […]
Read More ›